RxDoctor Payments Data

Lita Calagua, MD

Neurology · Davie, FLNPI 1932272010

Payments from drug & device makers

$9,382in general payments, 2019–2025

Across 501 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • AbbVie$1K
  • Lilly USA, LLC$831
  • Amneal Pharmaceuticals LLC$687
  • Teva Pharmaceuticals USA, Inc.$493
  • EMD Serono, Inc.$470
  • plus $5K from 37 others

What the payments were for

  • Speaking & faculty fees$471%
  • Food & beverage$9,29699%
  • Education$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,382 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$14,992
Medicare patients
37
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate21$105,173
AptiomEslicarbazepine Acetate27$47,388
NamzaricMemantine Hcl/Donepezil Hcl26$36,445
RexultiBrexpiprazole22$34,931
Memantine Hcl483$13,957
Rivastigmine42$7,326
Rasagiline Mesylate17$6,621
Levetiracetam113$3,843
Memantine Hcl ErMemantine Hcl19$2,832
Donepezil Hcl273$2,693
RivastigmineRivastigmine Tartrate41$2,380
Carbidopa-LevodopaCarbidopa/Levodopa75$1,853
Escitalopram Oxalate181$1,607
Primidone49$1,590
Quetiapine Fumarate64$1,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$99$105,17321 claims
Sunovion Pharmaceuticals Inc.Aptiom$384$47,38827 claims
AbbVieNamzaric$1,024$36,44526 claims
Otsuka America Pharmaceutical, Inc.Rexulti$371$34,93122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.

Other neurology in Davie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →